Our Team
Dr. Roy Ambinder
Founder, Chief Executive Officer, and Chief Scientific OfficerDr. Ambinder is an oncologist and hematologist, and a former partner of Florida Cancer Specialists and Research Institute. He brings decades of experience in oncology, hematology, clinical research, and biotechnology leadership. Dr. Ambinder graduated with honors in biology from Yale, earned his medical degree from Columbia University College of Physicians and Surgeons, and completed hematology and oncology fellowship training at Mount Sinai Medical Center. Dr. Ambinder chairs the board of Applied Applications for Cancer Therapy (AACT) Inc. He has participated in more than 120 research protocols, advised biotechnology companies, served on the executive boards of Florida Cancer Specialists and American Oncology Network, and founded BioStrategic Therapeutics.
Dr. E. Premkumar Reddy
Dr. Reddy is a pioneering cancer biologist, drug developer, and biotechnology entrepreneur. His research helped define how RAS and other oncogenes drive cancer, including seminal work on the molecular basis of leukemias and breast cancer. He has held scientific leadership roles at the National Cancer Institute, Roche, the Wistar Institute, Temple University, and Mount Sinai. Dr. Reddy is President and CEO of AACT Inc. and founder of Onconova Therapeutics (now Traws Pharma). He has published more than 250 papers, holds more than 100 patents, co-invented HIV diagnostic technology with Dr. Robert C. Gallo, and founded the journal Oncogene.
Research Advisor
Michael leads corporate development at Turritopsis Bio and is an attorney specializing in biotechnology startups. He has organized, led, and advised numerous early-stage drug development companies. He co-founded Axonyx Inc., then a publicly traded company developing Alzheimer’s disease treatments, and negotiated its key intellectual property, licensing, financing, and corporate transactions. At AngioGenex, he recruited leadership and scientific advisors, raised seed capital, and helped launch the company’s initial collaboration with Memorial Sloan Kettering. Earlier, he practiced corporate and litigation law and served as an assistant district attorney in the White Collar Crime Division of the Manhattan District Attorney’s Office.
Corporate DevelopmentMichael Strage, Esq.
Jeff serves as in-house IP counsel to Turritopsis Bio, directing patent and trademark procurement and licensing. He is the founding principal of Patent Networks Law Group, PLLC, and a biotechnology intellectual property attorney with three decades of experience. He advises life sciences companies, investors, universities, and research institutions on patent, trademark, copyright, licensing, and global IP strategy. His work includes patent procurement, portfolio analysis, freedom-to-operate opinions, transactions, and technology commercialization across human and veterinary drug development. Jeff has worked with organizations including the NIH, Scripps Research, Fred Hutchinson Cancer Center, Oxford University, the U.S. Department of Defense, and Memorial Sloan Kettering. His scientific background spans chemistry, biochemistry, molecular and cellular biology, immunology, and CNS drug development.
Intellectual Property
Jeff King, Esq.
Eric leads business affairs and operations at Turritopsis Bio. He is an attorney and family office leader with experience in corporate transactions, governance, and strategic operations. Before joining Turritopsis Bio, he served as technology counsel at Accenture and Avanade, advising leaders on complex commercial agreements and intellectual property matters. He works closely with Turritopsis Bio’s scientific and business leads on company formation, intellectual property strategy, partnerships, licensing, and growth. Eric has a JD from the University of Florida and a BA from the University of Michigan.
Business Affairs and OperationsEric Ambinder, Esq.
Mike leads all matters related to technology at Turritopsis Bio. He has a BA in Computer Science and Psychology from Yale University and a PhD in Psychology from the University of Illinois. For 15 years, he led research at Valve, working at the intersection of applied psychology and game design, with work spanning statistics, machine learning and AI, economic systems design, non-invasive brain-computer interfaces, and user experience research. Mike also serves as the Chief Research Officer of an independent research and consulting company.
Technology